Effect of CD55 single nucleotide polymorphism on the efficacy of pegylated interferon α-2b in chronic hepatitis B patients with HBeAg-positive
Objective To investigate the effect of CD55 single nucleotide polymorphism(CD55-SNP)on the efficacy of pegylated interferon α-2b(Peg-IFNα-2b)in chronic hepatitis B(CHB)patients with HBeAg-positive.Methods From August 2017 to August 2021,159 CHB patients with HBeAg-positive were selected.According to the results,CHB patients were divided into response group and non-response group.The clinical data of the two groups were retrospectively analyzed to explore the effect of CD55-SNP on the treatment of patients.Results The GG gene(91.4％)of CD55-rs28371597 was significantly higher than that of CT gene(6.4％)and TT gene(3.2％),and the CFB-rs12614 CC gene(92.4％)was significantly higher than that of CT gene(7.6％)and TT gene(0％)in the response group.Compared with the non-response group(75.0％,79.1％),the CD55-rs28371597 GG gene(91.4％)and CFB-rs12614 CC gene(92.4％)in the response group increased.According to the analysis of the influencing factors of the treatment effect,the comparison of drinking and CD55-rs28371597 genotype between the two groups was statistically significant.After multivariate calibration,HBV DNA,CFB-rs12614 and STAT4-rs7574865 did not affect the treatment outcome(P＞0.05),while CD55-rs28371597 significantly affected the treatment outcome(P＜0.05).Conclusion CD55-SNP polymorphism affects the efficacy of Peg-IFNα-2b in CHB patients with HBeAg-positive,and is closely related to virological response.Clinicians can predict the therapeutic effect of Peg-IFNα-2b according to the distribution of CD55-SNP polymorphism and give a reasonable treatment plan.
CD55 single nucleotide polymorphismHBeAgChronic hepatitis BPegylated interferon α-2bTherapeutic effect
万方数据
维普
